Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)
FDA’s Fast Track designation is intended to facilitate the development and expedite the review of new drugs to treat serious conditions and that fill an unmet medical need.
Dr. Hu replaces Jay Galeota, who recently stepped down from the Board.
Investors are invited to view the live presentation and participate in one-on-one meetings.
New Data Show Clinically Meaningful Improvements for Investigational Oral Pharmacologic Treatment AD504 in People with Obstructive Sleep Apnea
Apnimed data from a proof-of-concept study exploring two potential oral therapeutic candidates for treating OSA will featured in an oral presentation at SLEEP 2022.
Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders
Apnimed announced today that it has raised $62.5 million of committed capital in a Series C financing.
Apnimed will participate in 1×1 investor meetings at the 21st Needham Healthcare Conference taking place virtually April 11-14, 2022.
Apnimed will participate in the 32nd Annual Oppenheimer Conference taking place March 15-17, 2022 virtually.
Data from Apnimed’s Phase 2 study APC-004 will be featured in the company’s oral presentation at World Sleep 2022 in Rome, Italy on Monday, March 14.
Apnimed company management will participate in 1×1 investor meetings at the SVB Leerink Global Healthcare Conference.
Larry Miller, M.D., Chief Executive Officer, will present in a virtual format on Wednesday, January 12th at 5:30 p.m. ET.
GET APNIMED UPDATES